Corvus Pharmaceuticals (CRVS) Stock Forecast & Price Target
Score
Corvus Pharmaceuticals, Inc. price target
| CRVS | |
|---|---|
| Low | $27.00 |
| Average | $27.00 |
| High | $27.00 |
| Upside vs current price | +154.7% |
The average target of $27.00 is +154.7% versus the current CRVS price of $10.60.
Corvus Pharmaceuticals, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
7 analysts cover CRVS.
Corvus Pharmaceuticals, Inc. EPS and revenue estimates
CRVS shows the next fiscal years with at least three analysts: 2026 EPS $-0.75, 2027 EPS $-0.94. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.75 | $1.18M |
| 2027 | $-0.94 | $4.55M |
Is Corvus Pharmaceuticals, Inc. a buy or sell?
Of the 7 analysts covering Corvus Pharmaceuticals, Inc., 7 rate it a buy (1 strong buy and 6 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The CRVS consensus label is Buy, beside 7 buy-side ratings and 0 sell-side ratings.
The average target of $27.00 implies +154.7% versus the current price of $10.60.
Those 7 ratings on CRVS are a headcount, and the label on file is Buy.
Reading the Corvus Pharmaceuticals, Inc. forecast
The CRVS targets sit in a narrow band, from $27.00 to $27.00, around an average of $27.00.
Set next to the $10.60 CRVS quote, that average is +154.7%.
Ratings on the Corvus Pharmaceuticals, Inc. cluster: 7 of 7 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The CRVS average target is little changed, $27.00 over the last month and $27.00 over the last quarter.
Only 7 analysts cover CRVS, so the average rests on a short list.
Corvus Pharmaceuticals, Inc. forecast questions
What is the CRVS price target?
The published range for CRVS is $27.00 to $27.00, with an average of $27.00. That average is +154.7% versus the current price of $10.60.
Is Corvus Pharmaceuticals, Inc. a buy or sell?
Of the 7 analysts covering Corvus Pharmaceuticals, Inc., 7 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the CRVS headcount is 7 buy, 0 hold, and 0 sell.
What is the EPS estimate for Corvus Pharmaceuticals, Inc.?
Analyst EPS estimates for Corvus Pharmaceuticals, Inc.: 2026 $-0.75, 2027 $-0.94.
What is the revenue estimate for Corvus Pharmaceuticals, Inc.?
Analyst revenue estimates for Corvus Pharmaceuticals, Inc.: 2026 $1.18M, 2027 $4.55M.
How many analysts cover CRVS?
7 analysts cover CRVS. Their consensus on CRVS is Buy, across those 7.